# The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

> **NCT06563817** · PHASE2 · RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Communicating Hydrocephalus
- Cerebral Intraventricular Hemorrhage
- Secondary Normal Pressure Hydrocephalus
- Post Hemorrhagic Hydrocephalus

## Interventions

- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT06563817
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08
- **Primary completion:** 2025-05
- **Final completion:** 2025-07
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563817, "The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06563817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*